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ABSTRACT 
Background: The antibiotic lock (AL) technique is used for sterilization of 
the intraluminal surface of catheters. This technique consists of filling a cathe- 
ter lumen with an antibiotic solution and allowing it to dwell for a time sufficient 
to sterilize the device. Glycopeptide antibiotics (vancomycin and teicoplanin) 
are commonly used agents for this purpose. But studies evaluating the different 
dosages of these antibiotics, their optimum concentrations, and duration in AL 
treatment are lacking. 
Objective: The aim of this study was to compare the efficacy of different 
doses of vancomycin/saline solution (VSS) and teicoplanin/saline solution (TSS) 
and to establish the optimal dosage and time needed to eliminate intraluminal 
methicillin-resistant Staphylococcus epidermidis colonization. 
Methods: This in vitro AL study was conducted at the Department of 
Infectious Diseases and Clinical Microbiology, Adnan Menderes University 
Medical Faculty, Aydin, Turkey. Catheters were divided into 2 groups--those 
colonized with slime-forming S epidermidis, and those colonized with non- 
slime-forming S epidermidis. In each group, catheters were locked with VSS or 
TSS at 1-, 3-, and 5-mg/mL doses. Catheters instilled with saline solution were 
used as the control group. After 12 hours of incubation, the catheters were 
drained and filled with human plasma. Instillation of human plasma or AL solu- 
tion was alternated every 12 hours to simulate clinical conditions. Every other 
day, catheters locked with each antibiotic dose or saline were cultured to deter- 
mine colony count. These procedures were maintained until the catheters were 
sterile. 
Results: The baseline counts of slime-forming and non-slime-forming S epi- 
dermidis adhered to 1-cm segment catheters were 39 x 106 and 32 x 106 colony- 
forming units, respectively. The bacterial count was decreased significantly 
from baseline on the first day after the start of treatment (day 1) (P < 0.001). 
At the end of day 7, all catheters treated with antibiotics were sterile. The de- 
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creases in bacterial count were statistically similar in catheters treated with 
all doses of VSS and TSS. Also, the decrease in intraluminal colonization was 
statistically similar in catheters colonized with slime-forming S epidermidis and 
non-slime-forming S epiderrnidis. 
Conclusion: In this in vitro, blinded AL study, the efficacy of vancomycin and 
teicoplanin lock solutions were similar and sterilized the catheters in 7 days, 
suggesting that the 2 antibiotics might be selected for shorter durations com- 
pared with those currently recommended for AL treatment in catheter-related 
infections due to methicillin-resistant staphylococci. (Curr Ther Res Clin Exp. 
2005;66:364-374) Copyright © 2005 Excerpta Medica, Inc. 
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INTRODUCTION 
Central venous catheters (CVCs) have become ssential tools for the adequate 
management of patients in modern medical practice. 1 Each year, >20 million 
inpatients in the United States receive intravenous therapy, and almost 5 mil- 
lion require central venous catheterization. 2,3 In particular, the use of tunneled 
Broviac and Hickman catheters and totally implantable venous access devices 
(ports) has increased over the past few years. 4As a result of the use of these 
devices, infection has become a significant clinical problem. 
Currently, CVC-related infections (CVC-RIs) are among the most common 
types of nosocomial infections, and their prevalence may be increasing as 
intravascular catheters are used more frequently. 5 Rates of infections range 
between 2.8 and 12.8 episodes per 1000 catheter-days and might have a signifi- 
cant impact on patient morbidity and hospital costs. 2,s The migration of cuta- 
neous organisms at the insertion site into the CVC tract, with colonization of 
the catheter tip, is the most common route of infection in short-term (<10 days) 
catheterization. Contamination f the catheter hub contributes substantially to
intraluminal colonization in long-term (>10 days)catheterization. 2,s Coagulase- 
negative staphylococci have emerged as an important group of organisms in 
CVC-RIs (30%-40%), with Staphylococcus epiderrnidis being predominant, s,7 
Coagulase-negative staphylococci are capable of producing an exopolysaccha- 
ride biofilm ("slime") that mediates microbial adherence to biomaterial sur- 
faces. ~-1° Treatment failure often occurs in CVC-RIs because therapeutic levels 
of most antibiotics are not sufficient o kill microorganisms growing in the 
biofilm that lines catheter lumens. 
CVC removal has been considered an integral part of the therapeutic ap- 
proach to CVC-RIs. n However, removal of a CVC, particularly a tunneled CVC 
used for long-term catheterization in a critically ill patient, is associated with 
significant practical problems and costs .  4 In 1988, Messing et a112 reported the 
use of a new modality for the in situ treatment of CVC-RI that resulted in a 91% 
CVC salvage rate. This strategy, called antibiotic lock (AL), involves filling the 
CVC lumen with an antibiotic solution and allowing it to dwell for a time suffi- 
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cient to sterilize the device. 4The AL technique is a logical treatment method 
for uncomplicated (absence of hypotension or organ hypoperfusion, septic 
thrombosis, or septic emboli) CVC-Rls of intraluminal origin. To date, on the 
basis of the available data identified through a MEDLINE search (key term: 
antibiotic lock), several issues concerning the use of the AL technique remain 
unresolved. In particular, the usefulness of different types of antibiotics, their 
optimum concentrations, and the optimum duration of treatment need to be 
defined. 13 
The aim of this study was to compare the efficacy of different doses of van- 
comycin and teicoplanin lock solutions and to establish the optimal dosage and 
time needed to eliminate intraluminal S epidermidis colonization using a labora- 
tory AL model. 
MATERIALS AND METHODS 
This blinded, in vitro study was conducted at the Department of Infectious 
Diseases and Clinical Microbiology, Adnan Menderes University Medical Facul- 
ty, Aydin, Turkey. 
Bacterial Strains 
A single colony of slime-forming S epidermidis and a colony of non-slime- 
forming S epidermidis olated from CVC-RIs were used in the study. Clinical iso- 
lates were identified using Gram staining, catalase reaction, tube coagulation 
testing, and API Staph testing (bioM6rieux SA, Lyon, France). The ability of the 
S epidermidis strain to form a biofilm on an abiotic surface was determined as 
described elsewhere. 14Briefly, S epidennidis trains were grown overnight in 
Triptic soy broth (TSB) (Beckton, Dickinson and Company, Franklin Lakes, New 
Jersey) with 0.25% glucose at 35°C. The culture was diluted 1:40 in TSB with 
0.25% glucose, and 2 mL of this cell suspension was used to inoculate sterile poly- 
propylene conical bottom tubes (TPP, Trasadingen, Switzerland). After 48 hours 
at 35°C, the tubes were gently washed 3 times with 2 mL of phosphate-buffered 
saline, dried in an inverted position, and stained with 2 mL of 0.25% safranine 
0 for 2 minutes. The tubes were rinsed again and color development was ob- 
served; a positive result was indicated by the presence of an adherent layer of 
stained material on the inner surface of the tube. Slime formation was also 
shown quantitatively in 96-well polystyrene U-bottom microtiter plates (TPP), 
as described. 15The optical density of the content of the wells was determined 
at 595 nm (OD595) using a microplate reader (EL800, Bio-Tek Instruments, Inc., 
Winooski, Vermont). Strains with the same OD595 values at baseline were classi- 
fied as non-slime-forming S epidermidis. S epidermidis with OD~9 ~ values >2 
were considered slime-forming strains. Both isolates were resistant to methi- 
cillin. The MIC (determined using the broth microdilution testing method rec- 
ommended by the Clinical Laboratory Standards Institute [formerly NCCLS] 16) 
of each antibiotic for each isolate was 4 mg/L. 
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Antimicrobial Agents 
Vancomycin* and teicoplanint were prepared from their commercially avail- 
able formulations and mixed with 0.9% saline solution. AL solutions were pre- 
pared in concentrations of 1, 3, and 5 mg/mL. 
Catheters 
Polyurethane catheter segments, 16 G in diameter and -3 cm in length 
(Arrow International, Inc., Erding, Germany), were used in the study. The cathe- 
ters were divided into 2 groups--those colonized with slime-forming S epider- 
midis, and those colonized with non-slime-forming S epidermidis. Fifty-six 
catheters were included in each group. In each, catheters were locked with 
vancomycin/saline solution (VSS) or teicoplanin/saline solution (TSS) in 1-, 3-, 
and 5-mg/mL concentrations. Eight catheters were instilled with each dose of 
antibiotic; 8 catheters instilled with saline solution (SS) were used as the con- 
trol group. 
Experiments 
The experiments were conducted under sterile conditions. The catheters 
were clamped at the distal end, and human plasma was instilled into the 
catheters to allow deposition of fibrin and other products on the catheter 
walls. After 48 hours, the catheters were drained and inoculated intralumi- 
nally with bacteria in TSB suspension. The inoculated bacteria had been har- 
vested from overnight agar cultures and were inoculated to TSB to achieve 
a concentration of 1.5 x 10 ~ colony-forming units (CFU)/mL (0.5 McFarland). 
After inoculation, the catheters were incubated at 35°C for 48 hours. Sub- 
sequently, the catheters were drained and filled with VSS lock, TSS lock, or 
SS lock and incubated for 12 hours, after which all catheters were drained and 
filled with human plasma. Instillation of human plasma and AL was alternated 
every 12 hours to simulate clinical conditions. Every other day, 7 catheters, 
1 each locked with each antibiotic concentration or SS, were cultured to 
determine colony count. A 1-cm catheter segment cut from each sample was 
flushed with 2 mL of TSB solution and vortexed in the solution for 4 minutes 
at 2500 rpm at room temperature. The TSB solution in which the catheters 
were vortexed was serially diluted in TSB and plated on blood agar. Inocu- 
lated blood agar plates were incubated at 35°C for 24 hours. Microbial counts 
were expressed as the total number of CFU per longitudinal centimeter of 
catheter surface. The study was carried out until the catheters were sterile. 
Thereafter, the catheters were instilled only with human plasma for 3 days 
more to confirm sterilization. Experiments were conducted in triplicate on 
separate occasions, and the investigators were blinded to the contents of 
the catheters. 
*Trademark: Vancocin CP ® (Eli Lilly and Company, Indianapolis, Indiana). 
tTrademark: Targocid ® (Lepetit & Aventis, Levallois Perret, France). 
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Statistical Analysis 
General linear modeling for repeated measures was used to compare the rate 
of decline by log10 of colony counts over time. The differences between groups 
were tested for significance using the Kruskal-Wallis test, Wilcoxon signed rank 
test, and Mann-Whitney Utest, as appropriate. Differences were considered sig- 
nificant at P < 0.05. Statistical analysis was performed using SPSS version 10.0 
(SPSS Inc., Chicago, Illinois). 
RESULTS 
In the control group of catheters, bacterial counts >10 T CFU were maintained for 
both isolates until study end, confirming the viability ofS epidermidis nside the 
catheter. The baseline counts of slime-forming and non-slime-forming S epider- 
midis adhered to catheters were 39 × 106 CFU and 32 x 106 CFU, respectively. 
Bacterial counts decreased significantly from baseline starting on the first day 
after beginning treatment (day 1) (P< 0.001). At the end of day 7, all treated cathe- 
ters were sterile. The log10 values of microbial counts isolated from catheters 
throughout the study are presented in the table; the decline in bacterial count 
is presented in the figure. The decreases in bacterial counts were statistical- 
ly similar between catheters treated with all 3 concentrations of VSS and TSS. 
The decrease in intraluminal colonization was statistically similar between 
catheters colonized with slime-forming S epidermidis and those colonized with 
non-slime-forming S epidennidis. After day 7, the catheters were instilled only 
with human plasma and were cultured up to day 10. No bacteria were isolated 
after day 7 in the catheters treated with VSS or TSS. 
DISCUSSION 
Previous tudies assessing AL therapy in tunneled CVC-RI, with or without con- 
comitant parenteral therapy, have shown high rates of response and CVC 
salvage without relapse, uJ2,1T-21 Currently, in cases in which there is no indica- 
tion for catheter removal, systemic antibiotic therapy and AL therapy are rec- 
ommended for the treatment of tunneled CVC and implantable device-related 
bacteremia due to S epidermidis and other bacteria. 11 It is also possible to treat 
removable CVC-RIs caused by S epidermidis with catheter salvage. 11 In these 
instances, the recommended time for AL therapy is 10 to 14 days. u
In most of the previous studies, single doses of antibiotics were evaluated. 
Studies comparing different doses of the same antibiotic are lacking in the litera- 
ture. On the other hand, although the durations of those studies varied, most 
were 14 days. Evidence on which to base selection of the optimal anti- 
microbial agent, concentration, and duration of AL therapy is limited. In clinical 
practice, glycopeptide antibiotics are usually used at concentrations of 1 to 
5 mg/mL and dwelled in the catheter lumen for 12 hours. For this reason, we used 
concentrations of 1, 3, and 5 mg/mL of VSS and TSS dwelled for 12-hour periods. 
368 
S. Oncu  and S. Sokarya 
0 0 0  0 0 0  0 0 0  0 0 0  
V V V  V V V  V V V  V V V  
II 
I l l  I l l  I l l  I I  
. - -  ~ ~ ~ ~ ~ ~ 
~ ~ ~ ~ ~ ~ ~o ~ ~ ~ ~ ~ ~ ~ ~ " .~  
"~ ~ 
~8 =~ ~ ~ ~ ~ ~ ~ - ~  ~ E E E E .  E E E ~ E E E .  E E E ~ • - -   ~ ~ 
oo  ~ ~ ~ 
-- ~ 
369 
CURRENT THERAPEUTIC RESEARCH 
Figure. 
_ 
"~o 7 -  
O ~., 6-  
"~ 5-  
o 
U 4-  
om 
e~ 
.o 3 -  
2 -  
1 -  
0 I I I I 
0 1 3 5 7 
Study Day 
Decrease in microbial count at days 1, 3, 5, and 7 after beginning treatment 
with vancomycin and teicoplanin lock solutions. 
In the present study, significant decreases in bacterial count were detected 
at all 3 doses on day 1. This decrease continued steadily, and at day 5 the 
counts were <103 CFU, the level accepted as the threshold for CVC coloniza- 
tion. 5 These decreases were statistically similar between all catheters treated 
with the 2 antibiotics at all 3 doses. All of the treated catheters were sterile at 
the end of day 7, which is shorter compared with the duration of the current 
recommendation for AL therapy. 11 The initial bacterial count in the present 
study would be expected to be higher than is usually found in clinical prac- 
tice. 22 Therefore, the required time to sterilize the catheters might be <7 days. 
However, because it is not possible to predict he number of organisms in sal- 
vaged catheters, 7 days might be accepted as the upper limit of the duration of 
AL therapy. A limited number of previous in vitro AL studies also showed a 
significant reduction in bacterial count several days after the start of treat- 
ment. 23-25 Doses or dwell times of antibiotics or the counts of bacteria coloniz- 
ing the catheters at the beginning of AL therapy were different from those in the 
present study. These differences might have resulted in the variation in the time 
required to sterilize the catheters in previous tudies compared with that in the 
present study. 
The unnecessary use of glycopeptide antibiotics is known to contribute 
to the development of glycopeptide-resistant, gram-positive organisms. 4,26,27 
Infections due to these resistant organisms are difficult to treat and result in 
increased morbidity and mortality. One way to prevent he emergence of these 
resistant organisms is to use antibiotics more carefully. Although the current 
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guideline recommends therapy for 10 to 14 days, our study suggests that a 
shorter duration (~7 days) of AL treatment with glycopeptides might be suf- 
ficient to treat catheters. Most studies of AL treatment to date have used a 
14-day treatment period. 11JT,2s However, the study with the lowest salvage rate 
reported that a mean of 8 days of treatment was sufficient, 18 supporting the 
findings in the present study. Further prospective clinical trials are required to 
determine the in vivo relevance of these findings. 
In the presence of slime, the antimicrobial susceptibility of bacteria is al- 
tered, with the MIC often shifting toward the range of resistance, s The anti- 
microbial resistance of the bacteria in the biofilm might be associated with 
restricted iffusion of antimicrobials through the biofilm matrix, physiologic 
changes and gene expression or repression due to the mode of growth of the 
biofilm, and/or a decreased growth rate of bacteria in the biofilm. 29-35 In AL 
therapy, high concentrations of antibiotics are used, and we examined whether 
these high concentrations would overcome the effect of the slime. Our findings 
indicate that slime-forming S epidermidis colonization was as successfully 
treated as non-slime-forming S epidermidis colonization, which suggests that 
contact with a highly concentrated anti-infective solution within the catheter 
lumen is effective in eliminating adherent organisms, whether or not they 
form slime. 
Glycopeptides are bactericidal to most actively dividing susceptible bacte- 
ria, as are other cell wall-active agents. 36 Vancomycin has been in use since 
1956 and has been used extensively in staphylococcal infections, including 
those caused by methicillin-resistant strains. 36 The major drawbacks of vanco- 
mycin use are histamine-induced reactions, thrombocytopenia, and ototoxic- 
ity. 36 Teicoplanin has the potential for use as an alternative to vancomycin i  
the treatment of gram-positive bacterial infections, especially those caused by 
methicillin-resistant pathogens. Although similar to vancomycin in structure, 
mechanism of action, and in vitro activity, teicoplanin has been associated with 
less vestibular toxicity and ototoxicity compared with vancomycin. 36 However, 
with AL therapy, a high concentration f glycopeptide antibiotic an be applied 
in the catheter lumen, while systemic toxicity and the need for monitoring 
serum drug concentrations are avoided. 37 But studies comparing these glyco- 
peptide antibiotics in AL therapy are lacking. Vancomycin for AL therapy has 
been assessed in many studies, 19,23-25,38,39 but teicoplanin has been assessed in 
few. 4°-43 Although some studies support he effectiveness of teicoplanin in AL 
therapy, studies conducted by Guedon et al 4° and Longuet et a143 showed lim- 
ited efficacy. 
There is no universally accepted in vitro model of CVC infection and AL ther- 
apy, which is a limitation of the present study. Although the AL model used was 
intended to simulate clinical conditions as closely as possible, the conditions in 
the in vivo environment may have different effects on the growth of bacteria 
and the success of the therapy. Therefore, the results of our in vitro AL study 
should be confirmed in clinical trials. 
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CONCLUSION 
In this in vitro, bl inded AL study, the efficacy of vancomycin  and teicoplanin 
lock solutions were similar and steril ized the catheters  in 7 days, suggesting 
that the 2 antibiotics might be selected for shor ter  durat ions compared  with 
those current ly recommended for AL t reatment  in catheter-related infections 
due to methici l l in-resistant staphylococci .  
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